Boyella V, Onyebueke I, Farraj N, Graham-Hill S, Younis CE, Bergasa NV

Language: English
References: 24
Page: 113-115
PDF size: 36.09 Kb.

Text Extraction

Chronic hepatitis C can be associated with extrahepatic manifestations; thus, we explored the association of this viral infection with dilated cardiomyopathy in a group of sixty-three patients with a cardiac ejection fraction of less than 40% determined by an echocardiogram in a prospective study. Two of the forty-one patients with non-ischemic cardiomyopathy (4.8%) had serum antibodies to the hepatitis C virus and one of those had hepatitis C virus RNA (2.4%) in serum, consistent with chronic hepatitis C. One of the 22 patients with ischemic cardiomyopathy (4.5%) had serum antibodies to the hepatitis C virus but the hepatitis C virus RNA was not detected in their serum, consistent with prior infection but not chronic hepatitis C. In this study, chronic hepatitis C was not prevalent in the group of patients, although the only patient with chronic hepatitis C had non-ischemic cardiomyopathy. As a genetic predisposition to develop cardiomyopathy secondary to chronic hepatitis C has been suggested to be relevant in this type of complication, studies that include different racial and ethnic groups are warranted, as treatment of the hepatitis may lead to resolution of the cardiomyopathy.

REFERENCES

1. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79(1): 47-56.

2. DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17(4): 551-7.

3. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46(6): 1700-4.

4. Jubert C, Pawlotsky JM, Pouget F, et al. Lichen planus and hepatitis C virus—related chronic active hepatitis. Arch Dermatol 1994; 130(1): 73-6.

5. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases. Medicine (Baltimore) 2001; 80(1): 1-8.

6. Matsumori A. Hepatitis C virus and cardiomyopathy. Herz 2000; 25(3): 249-54.

7. Matsumori A, Ohashi N, Nishio R, et al. Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Jpn Circ J 1999; 63(6): 433-8.

8. Matsumori A, Ohashi N, Sasayama S. Hepatitis C virus infection and hypertrophic cardiomyopathy. Ann Intern Med 1998; 129(9): 749-50.

9. Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 1998; 62(5): 389-91.

10. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995; 92(9): 2519-25.

11. Billingham ME, Tazelaar HD. The morphological progression of viral myocarditis. Postgrad Med J 1986; 62(728): 581-4.

12. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99(8): 1091-100.

13. O’Connell J. The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Ins J 1987; 14: 268-275.

14. Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000; 80(7): 1137-42.

15. Teragaki M, Nishiguchi S, Takeuchi K, Yoshiyama M, Akioka K, Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels 2003; 18(4): 167-70.

16. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 2006; 12(4): 293-8.

17. Sanchez MJ, Bergasa NV. Hepatitis C associated cardiomyopathy: potential pathogenic mechanisms and clinical implications. Med Sci Monit 2008; 14(5): RA55-63.

18. Prati D, Poli F, Farma E, et al. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). J Med Virol 1999; 58(2): 116-20.

19. Reis FJ, Viana M, Oliveira M, Sousa TA, Parana R. Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study. Braz J Infect Dis 2007; 11(3): 318-21.

20. Dos Reis FJ, de Sousa TA, Oliveira MS, et al. Is hepatitis C virus a cause of idiopathic dilated cardiomyopathy? A systematic review of literature. Braz J Infect Dis 2006; 10(3): 199-202.

21. Iskandar SB, Loyd S, Downs CJ, Roy TM. Hepatitis C and dilated cardiomyopathy. Tenn Med 2004; 97(1): 31-3.

22. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005; 96(2): 144-7.

23. Shichi D, Kikkawa EF, Ota M, et al. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens 2005; 66(3): 200-8.

24. McMurray J, Pfeffer M. Heart failure. The Lancet 2005; 365: 1877-1889.